Figure 5
From: Immunomodulatory role of Parkinson’s disease 7 in inflammatory bowel disease
Effect of PARK7-binding Comp23 on DSS induced colitis of mice. In each treatment group body-weight loss (a) and disease activity index (b) were investigated for 10 days, spleen samples (c) were removed and weighed on the 7th and 10th days, HE and PAS staining and histological examination (d, e), and the molecular biological measurements (f–l) were done from colon samples removed on the 7th day of the experiment (n = 5–7). Black arrows indicate the accumulated inflammatory cells and damaged crypts and microvilli. Scale bar: 1 mm or 200 µm. The mRNA expression of Tnfa (f), Tgfb1 (g), Il1b (h), Il6 (i) and Il10 (j) was determined by real-time PCR (f–j), and the protein level of PARK7 (k, l) by Western blot (k, l) (n = 5–7). Relative expression or amount of PARK7 are presented in comparison with Rn18S mRNA (f–j) or ß-actin protein (k, l) as internal control and normalized to Control group, respectively. Results are illustrated as mean + SEM, dots represent individual values. Analysis of significance was performed by two-way ANOVA test. *p < 0.05 Control vs. DSS at given day, **p < 0.05 DSS vs. DSS + Comp23 at given day, #p < 0.05 comparing the connected groups. Full-length blots are included in “Supplementary Informations”.
